DR. WOLF BIOSCIENCE
As a sole trader I have been engaged since 1994 in development and marketing of a new class of pharmacologically active compounds – oxirane carboxylic acids. Since 1979 I have also been involved as co-inventor and holder of numerous patents relating to the development and investigation of etomoxir, one compound of this new class of pharmacologically active compounds.
Etomoxir
Etomoxir reached phase II of clinical development as a new drug candidate for type 2 diabetes and heart failure at Byk Gulden Pharmaceuticals, later ALTANA AG, Constance, Germany, and MediGene AG, Planegg/Martinsried, Germany. Both companies discontinued this promising development prematurely. In light of current knowledge, this decision appears questionable. Etomoxir remains the only specific and highly potent irreversible inhibitor of carnitine palmitoyltransferase 1 (E.C. 2.3.1.21), the mitochondrial enzyme that regulates the transport of long-chain fatty acids into mitochondria. It is therefore still used as an experimental tool to investigate inhibition of long-chain fatty acid oxidation.
Aim
My aim today is to provide etomoxir and its derivatives in reliable quality at a reasonable price and to make the accumulated scientific knowledge on etomoxir available. In this way I continue the work of the BioScience Beteiligungs Anstalt (LI), which was dissolved in 2013.
| Curriculum vitae – Dr. Horst P. O. Wolf |
| Born 1941 in Leipzig, married, 5 children, German citizenship. |
| Study of chemistry and biochemistry at the Technical High School Leuna-Merseburg and the Friedrich Schiller University of Jena, Germany. |
| Doctorate at the Faculty of Veterinary Medicine, University of Leipzig, Germany, in 1970. |
| 5 years as director of clinical chemical laboratories at the Children’s Hospital of the University of Leipzig, Germany. |
| 19 years as senior scientist in the research laboratories of Byk Gulden Pharmaceuticals GmbH, Constance, Germany. |
| Member of the European Association for the Study of Diabetes. |
| Since 1994 sole trader and scientific consultant. |
| Author and co-author of numerous scientific publications and inventor or co-inventor of drugs, for example Daxas. |
| Languages: German, English. |
After inhibition of CPT 1 by etomoxir, fatty acid utilization is limited and other substrates such as glucose, lactate and ketones are used for energy production. Glucose oxidation theoretically requires less oxygen for the same energy yield. More
Etomoxir inhibits ketogenesis and gluconeogenesis and increases glucose oxidation in fasted and diabetic animals as well as in humans by lowering the rate of long-chain fatty acid oxidation. More
Over the last two decades, several reports have described anti-proliferative properties of etomoxir. More recent work has renewed interest in its possible therapeutic role in cancer research. More
Increased fatty acid oxidation and insulin resistance are associated with chronic inflammatory processes. Etomoxir is described here in the context of inflammatory disease mechanisms and possible therapeutic relevance. More
Ketosis is a severe metabolic disease in dairy cows with high milk production during the peripartum period. This section outlines why etomoxir was investigated in this field. More
The following substances can be delivered for experimental use only. This section provides the current overview of the available compounds. More
